Scarica l'app Stockscreener
38.48
1.08%
-0.42
Pre-mercato:
38.11
-0.37
-0.96%
Precedente Chiudi:
$38.90
Aprire:
$38.17
Volume 24 ore:
944.82K
Relative Volume:
1.00
Capitalizzazione di mercato:
$3.07B
Reddito:
$541.74M
Utile/perdita netta:
$88.01M
Rapporto P/E:
35.43
EPS:
1.0862
Flusso di cassa netto:
$155.34M
1 W Prestazione:
-4.80%
1M Prestazione:
+13.04%
6M Prestazione:
-2.21%
1 anno Prestazione:
+35.06%
Intervallo 1D:
$37.72
$39.57
Intervallo di 1 settimana:
$37.66
$40.97
Portata 52W:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Nome
Veracyte Inc
Settore
Industria
Telefono
(650) 243-6300
Indirizzo
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
38.48 | 3.10B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | Jefferies | Buy |
| 2025-12-02 | Ripresa | Morgan Stanley | Underweight |
| 2025-10-20 | Iniziato | Canaccord Genuity | Hold |
| 2025-03-20 | Iniziato | Craig Hallum | Buy |
| 2024-12-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-16 | Iniziato | UBS | Buy |
| 2024-10-10 | Iniziato | Guggenheim | Buy |
| 2024-02-23 | Reiterato | Needham | Buy |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-11-18 | Ripresa | Goldman | Buy |
| 2021-06-15 | Iniziato | Raymond James | Outperform |
| 2021-02-18 | Ripresa | Needham | Buy |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2019-07-31 | Iniziato | Lake Street | Buy |
| 2019-07-02 | Iniziato | Needham | Buy |
| 2018-11-29 | Downgrade | Janney | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-07 | Downgrade | Janney | Buy → Neutral |
| 2017-11-07 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Ripresa | BTIG Research | Buy |
| 2016-11-14 | Ripresa | Leerink Partners | Outperform |
| 2015-12-18 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-11 | Reiterato | Leerink Partners | Outperform |
| 2013-11-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Veracyte Inc Borsa (VCYT) Ultime notizie
Veracyte stock (US92347M1009): earnings momentum and cancer diagnostics focus - AD HOC NEWS
Veracyte Secures Medicare Coverage for Bladder Cancer Monitoring Test - Moomoo
Veracyte (VCYT) Gains CMS Coverage for TrueMRD Monitoring Test - GuruFocus
Veracyte Gains Medicare Coverage for Muscle-Invasive Bladder Cancer Recurrence Monitoring Test - Contract Pharma
Veracyte’s TrueMRD Monitoring Test receives coverage from CMS - TipRanks
Veracyte’s bladder cancer test receives Medicare coverage - Investing.com
Veracyte secures Medicare coverage for Truemrd monitoring test in muscle-invasive bladder cancer - marketscreener.com
Veracyte Secures Medicare Coverage For Truemrd Monitoring Test In Muscle-Invasive Bladder Cancer - TradingView
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer - New Castle News
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings - simplywall.st
Statutory Profit Doesn't Reflect How Good Veracyte's (NASDAQ:VCYT) Earnings Are - Yahoo Finance
Veracyte Inc (VCYT) Shares Fall 3.3% -- What GF Score of 82 Tells Investors - GuruFocus
Artisan Partners (NYSE: VCYT) reports 5.50M shares, 6.9% stake in Veracyte - Stock Titan
Morgan Stanley Initiates Veracyte(VCYT.US) With Sell Rating, Announces Target Price $39.7 - Moomoo
State Street (VCYT) discloses 5.04M-share, 6.3% holding in Veracyte - Stock Titan
State of New Jersey Common Pension Fund D Invests $1.13 Million in Veracyte, Inc. $VCYT - MarketBeat
Veracyte | 4: Statement of changes in beneficial ownership of securities-Officer Stapley Marc - Moomoo
Why Veracyte Stock Is Skyrocketing Higher This Week - AOL.com
Veracyte (VCYT) Is Up 23.8% After Raising 2026 Guidance And Expanding Decipher Cancer Studies - simplywall.st
Veracyte (VCYT) Q1 2026 Earnings: Revenue Up 21%, EPS Quadruples, Shares Climb 23%News and Statistics - IndexBox
Veracyte, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VCYT) 2026-05-08 - Seeking Alpha
Insider Sell: Annie Mcguire Sells 10,204 Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte SVP McGuire sells $398,211 in shares By Investing.com - Investing.com South Africa
Veracyte SVP McGuire sells $398,211 in shares - Investing.com
Veracyte (VCYT) general counsel sells 10,204 shares in 10b5-1 plan - Stock Titan
Veracyte, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors - Yahoo Finance
Number of shareholders of Veracyte, Inc. – MUN:12V - TradingView
Veracyte price target raised to $42 from $40 at Canaccord - TipRanks
Veracyte (VCYT) Margin Expansion And 166% Earnings Growth Test Premium Valuation Narratives - Sahm
VCYT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
The Nasdaq Biotechnology Index closed up more than 2.1%. Among its constituents, Pyxis Oncology rose 25.68%, Veracyte gained 25.08%, MannKind (MNKD) increased 24.83%, Replimune was up 19.16%, and Novavax (NVAX) rose 15.56%. - Bitget
Veracyte (VCYT) Jumps As Strong Q1 Fuels Bullish Guidance - timothysykes.com
Ann McGuire sells 6,658 shares under 10b5-1 plan (VCYT) - Stock Titan
Veracyte Surges 21.1% Amid Sector-Wide Rally - AlphaStreet
UBS Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $52 - Moomoo
Veracyte, Inc. Q1 2026 Financial Report: Forward-Looking Statements, Key Risks, and Results Overview - Minichart
VCYT Stock Jumps As Raised Guidance Fuels Bullish Momentum - StocksToTrade
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
FMR LLC (NASDAQ: VCYT) discloses 9.7% holding — 7.7M shares - Stock Titan
UBS Adjusts Price Target on Veracyte to $52 From $48, Maintains Buy Rating - marketscreener.com
A Quick Look at Today's Ratings for Veracyte(VCYT.US), With a Forecast Between $42 to $48 - Moomoo
Veracyte, Inc. (NASDAQ:VCYT) Q1 2026 Earnings Call Transcript - Insider Monkey
Veracyte, Inc. 1Q 2026: Revenue $139.07M, EPS $0.35— 10-Q Summary - TradingView
Veracyte (NASDAQ: VCYT) Q1 profit surges as revenue climbs 21% - Stock Titan
Veracyte Q1 2026 slides: EPS beats by 57%, guidance raised - Investing.com Australia
Veracyte Q1 Non-GAAP Earnings, Revenue Rise; Raises 2026 Revenue Guidance; Shares Up Pre-Bell - marketscreener.com
Veracyte: Raising FY26 Testing Rev Guidance to $570M to $580M >VCYT - Moomoo
Veracyte Announces First Quarter 2026 Financial Results - BioSpace
Veracyte Q1 Earnings Call Highlights - Yahoo Finance
Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates - sharewise.com
Veracyte Inc Azioni (VCYT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):